| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20070029 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20028064 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20069518 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20030467 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20028056 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20069519 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20064299 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20028053 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20069520 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
| TVIS20064235 | HPV | ENSG00000101868.13 | protein_coding | POLA1 | No | No | 5422 | A6NMQ1 P09884 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | POLA1 |
|---|---|
| DrugBank ID | DB00631 |
| Drug Name | Clofarabine |
| Target ID | BE0000546 |
| UniProt ID | P09884 |
| Regulation Type | inhibitor |
| PubMed IDs | 17139284; 17016423; 20631817; 15230627; 18780321; 18728851; 17852710; 19519505; 19576186 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Pession A, Masetti R, Kleinschmidt K, Martoni A: Use of clofarabine for acute childhood leukemia. Biologics. 2010 Jun 24;4:111-8.@@Authors unspecified: Clofarabine. Drugs R D. 2004;5(4):213-7.@@Musto P, Ferrara F: Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia. Cancer. 2008 Oct 15;113(8):1995-8. doi: 10.1002/cncr.23804.@@Harned TM, Gaynon PS: Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag. 2008 Apr;4(2):327-36.@@Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.@@Lech-Maranda E, Korycka A, Robak T: Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Mini Rev Med Chem. 2009 Jun;9(7):805-12.@@Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1. |
| Groups | Approved; Investigational |
| Direct Classification | Purine 2'-deoxyribonucleosides |
| SMILES | [H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12 |
| Pathways | |
| PharmGKB | PA164754863 |
| ChEMBL | CHEMBL1750 |
